Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The PP2A-B56α Heterocomplex Regulates Response to Venetoclax Plus Azacitidine Treatment in AML

Silvia Romero-Murillo, Irene Peris, Nerea Marcotegui, Carmen Vicente, Maria D. Odero, Goutham Narla

Blood (2023) 142 (Supplement 1): 2784.

https://doi.org/10.1182/blood-2023-174496

Published: 2023

Journal Articles

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Irene Peris, Silvia Romero-Murillo, Elena Martínez-Balsalobre, Caroline C. Farrington, Elena Arriazu, Nerea Marcotegui, Marta Jiménez-Muñoz, Cristina Alburquerque-Prieto, Andrea Torres-López, Vicente Fresquet, Jose A. Martínez-Climent, Maria C. Mateos, Maria L. Cayuela, Goutham Narla, Maria D. Odero, Carmen Vicente

Blood (2023) 141 (9): 1047–1059.

https://doi.org/10.1182/blood.2022016466

Published: 2023

Includes: Supplemental data

Journal Articles

RUNX1 and GATA2 Regulate the Expression of the SET Oncogene in Acute Myeloid Leukemia

Raffaella Pippa, PhD, Ana Dominguez, Bsc, Nerea Marcotegui, Bsc, Raquel Malumbres, PhD, Elizabeth Guruceaga, Maria D. Odero, MD, PhD

Blood (2014) 124 (21): 879.

https://doi.org/10.1182/blood.V124.21.879.879

Published: 2014

Journal Articles

OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias

Anupriya Agarwal, Ryan J. Meckenzie, B.S., Raffaella Pippa, Ph.D., Christopher A. Eide, Jessica Oddo, B.S., Jeffrey W. Tyner, Rosalie Sears, Ph.D., Michael P. Vitek, Ph.D., Maria D. Odero, M.D., Ph.D., Dale J. Christensen, Ph.D., Brian J. Druker

Blood (2013) 122 (21): 2511.

https://doi.org/10.1182/blood.V122.21.2511.2511

Published: 2013

Journal Articles

Reactivating PP2A by FTY720-Loaded Lipid Nanoparticles, a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Ander Estella-Hermoso de Mendoza, Ph.D., Remedios Castello-Cros, Ph.D., Cristina Cirauqui, B.Sc., Raffaella Pippa, Ph.D., Isabel Moreno, Ph.D., Maria J Blanco-Prieto, Ph.D., Maria D Odero, MD, Ph.D.

Blood (2012) 120 (21): 1511.

https://doi.org/10.1182/blood.V120.21.1511.1511

Published: 2012

Journal Articles

Functional Analysis of the GATA2 Promoter Shows That Mutations of GATA2 Impair Its Own Transcriptional Regulation

Xabier Cortes-Lavaud, M.Sc., Miren Maicas, Ph.D., Iria Vazquez, Ph.D., Carmen Vicente, Ph.D., Leire Urquiza, M.Sc., Maria A Garcia-Sanchez, Ph.D., Maria D Odero, MD, Ph.D.

Blood (2012) 120 (21): 1233.

https://doi.org/10.1182/blood.V120.21.1233.1233

Published: 2012

Journal Articles

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Marta Fernandez-Mercado, Andrea Pellagatti, Janet Perry, Cristina Fernandez-Santamaria, Maria J. Calasanz, Maria J. Larrayoz, Maria D. Odero, Sally Killick, James S. Wainscoat, Jacqueline Boultwood

Blood (2010) 116 (21): 2940.

https://doi.org/10.1182/blood.V116.21.2940.2940

Published: 2010

Journal Articles

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

Ion Cristóbal, Francisco J. Blanco, Laura Garcia-Orti, Nerea Marcotegui, Carmen Vicente, José Rifon, Francisco J. Novo, Eva Bandres, María J. Calasanz, Carmelo Bernabeu, María D. Odero

Blood (2010) 115 (3): 615–625.

https://doi.org/10.1182/blood-2009-06-227363

Published: 2010

Includes: Supplemental data

Journal Articles

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

Carmen Vicente, Ph.D., Ana Conchillo, Ph.D., Daphnie Pauwels, BSc, Iria Vazquez, Ph.D., Laura Garcia-Orti, BSc, Maria J. Calasanz, Ph.D., Idoya Lahortiga, Ph.D., Jan Cools, Ph.D., Maria D. Odero, MD, Ph.D.

Blood (2009) 114 (22): 2402.

https://doi.org/10.1182/blood.V114.22.2402.2402

Published: 2009

Journal Articles

Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC.

Iria Vazquez, BSc, José Cervera, MD, PhD, Maria Gomez-Benito, Ph.D., Nerea Marcotegui, BSc, Miren Maicas, BSc, Ana Conchillo, Ph.D., Ana Valencia, Ph.D., Eva Lumbreras, Ph.D., Salut Brunet, MD, Maria T. Gómez-Casares, MD, Ph.D., Jesus-Maria Hernandez-Rivas, MD, Ph.D., Maria J. Calasanz, PhD, Jorge Sierra, MD, PhD, Maria D. Odero, MD, PhD

Blood (2008) 112 (11): 1515.

https://doi.org/10.1182/blood.V112.11.1515.1515

Published: 2008

Journal Articles

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Idoya Lahortiga, PhD, Carlos Graux, MD, Nicole Mentens, Katrien Van Roosbroeck, Kim De Keersmaecker, Frederic Lambert, MD, Peter Vandenberghe, MD, Iwona Wlodarska, PhD, Guy Froyen, PhD, Maria D. Odero, PhD, MD, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 4469.

https://doi.org/10.1182/blood.V108.11.4469.4469

Published: 2006

Journal Articles

Genetic Aberrations and Response to Fludarabine as First Line Treatment in a Serie of B-CLL Patients.

Pilar Giraldo, MD, PhD, Araceli Rubio-Martinez, MDPhD, Valle Recasens, MD, Mikel Valganon, MD, Paz Latre, MD, Daniel Rubio-Felix, MDPhD, Maria J. Calasanz, MDPhD, Maria D. Odero, MDPhD

Blood (2005) 106 (11): 2131.

https://doi.org/10.1182/blood.V106.11.2131.2131

Published: 2005

Journal Articles

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

Idoya Lahortiga, PhD, Iria Vazquez, BSc, Nerea Marcotegui, BSc, Eva Bandres, PhD, Raquel Malumbres, PhD, Maria J. Larrayoz, BSc, Carmen Vicente, BSc, Jose Cervera, MD, PhD, Jesus M. Hernandez, MD, PhD, Jesus Garcia-Foncillas, MD, PhD, Maria T. Ardanaz, MD, Filomena Floristan, MD, Maria J. Calasanz, PhD, Maria D. Odero, MD, PhD

Blood (2005) 106 (11): 2378.

https://doi.org/10.1182/blood.V106.11.2378.2378

Published: 2005

Journal Articles

CML and Imatinib Mesylate: Response Related to Karyotype.

Araceli Rubio-Martinez, MD, PhD, Valle Recasens, MD, Maria D. Odero, MDPhD, Daniel Rubio-Felix, MDPhD, Maria J. Calasanz, MDPhD, Pilar Mayayo, MD, Manuel Giralt, MDPhD, Pilar Giraldo, MDPhD

Blood (2005) 106 (11): 4866.

https://doi.org/10.1182/blood.V106.11.4866.4866

Published: 2005

Journal Articles

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

Kim De Keersmaecker, Carlos Graux, Maria D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Wlodarska, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, Jan Cools

Blood (2005) 105 (12): 4849–4852.

https://doi.org/10.1182/blood-2004-12-4897

Published: 2005

Journal Articles

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Jan Cools, Nicole Mentens, Maria D. Odero, Pieter Peeters, Iwona Wlodarska, Michel Delforge, Anne Hagemeijer, Peter Marynen

Blood (2002) 99 (5): 1776–1784.

https://doi.org/10.1182/blood.V99.5.1776

Published: 2002

NARROW

The PP2A-B56α Heterocomplex Regulates Response to Venetoclax Plus Azacitidine Treatment in AML

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

RUNX1 and GATA2 Regulate the Expression of the SET Oncogene in Acute Myeloid Leukemia

OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias

Reactivating PP2A by FTY720-Loaded Lipid Nanoparticles, a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Functional Analysis of the GATA2 Promoter Shows That Mutations of GATA2 Impair Its Own Transcriptional Regulation

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC.

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Genetic Aberrations and Response to Fludarabine as First Line Treatment in a Serie of B-CLL Patients.

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

CML and Imatinib Mesylate: Response Related to Karyotype.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only